Market Overview

Competitor Analysis 2018: Tumor Microenvironment Modulation via IDO, TGF-ß, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING - ResearchAndMarkets.com

Share:

The "Competitor
Analysis: Tumor Microenvironment Modulation via IDO, TGF-ß, CXCR4,
CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018"
report
has been added to ResearchAndMarkets.com's offering.

This report analyzes the competitive field of modulators of the tumor
microenvironment via IDO & TDO, TGF-beta/R, CXCR4, novel chemokines,
CSF-1R, CD47-SIRPalpha, adenosine pathway incl. CD73/CD39 and STING as
of July 2018 in a tabulated format with structured listings of
industry-relevant data. The report describes the lead indications of
each unique molecule in the most advanced R&D stage.

The mainly selective, but also bispecific new molecular entities
modulate the tumor microenvironment by targeting:

  • IDO (Indoleamine 2,3-dioxygenase)
  • TDO (Tryptophan 2,3 dioxygenase)
  • TGF-β/R (Transforming Growth Factor beta/Receptor)
  • CXCR4 (Chemokine Receptor Type 4)
  • Novel Chemokines (e.g. CCR2, CCR4, CXCL2, CXCR2, IL-8)
  • CSF-1R (Colony Stimulating Factor-1 Receptor)
  • CD47-SIRPα (Signal Regulatory Protein Alpha)
  • Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
  • STING (STimulator of INterferon Genes) Receptor
  • Others (e.g. arginase)

At least 77 new molecular entities (NMEs) modulating the tumor
microenvironment are in clinical development as monotherapy or in
combination with checkpoint modulators or other active principles. At
least 26 further NMEs are undergoing IND-enabling studies and numerous
preclinical approaches are under evaluation.

The report includes a compilation of currently active projects in
research and development of new molecular entities modulating the tumor
microenvironment by targeting IDO & TDO, TGF-beta/R, CXCR4, novel
chemokines, CSF-1R, CD47-SIRPalpha, adenosine pathway incl. CD73/CD39
and STING. In addition, the report lists company-specific R&D pipelines
of modulators of the tumor microenvironment.

Competitor projects are listed in a tabular format providing
information on:

  • Drug Codes
  • Target / Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication
  • R&D Stage
  • Additional comments with a hyperlink leading to the source of
    information

For more information about this report visit https://www.researchandmarkets.com/research/wb5dns/competitor?w=4

View Comments and Join the Discussion!